Intra-Cellular Therapies (NASDAQ:ITCI) Rating Reiterated by Cantor Fitzgerald

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a note issued to investors on Wednesday, Benzinga reports. They presently have a $120.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 66.37% from the stock’s […]

Related Keywords

Canada ,United States ,America ,Robertw Baird ,Lawrencej Hineline ,Kapitalo Investimentos Ltda ,Royal Bank ,Canaccord Genuity Group ,Ci Investments Inc ,Cellular Therapies Inc ,Cantor Fitzgerald ,Cape Investment Advisory Inc ,Securities Exchange Commission ,Intra Cellular Therapies ,Get Free Report ,Genuity Group ,Cellular Therapies Stock Down ,Cellular Therapies ,Exchange Commission ,Investimentos Ltda ,Ivy Capital Management ,Investment Advisory ,Intra Cellular Therapies Daily ,Nasdaq Itci ,Bitci ,Medical ,Reiterated Rating ,